Contact this trialFirst, we need to learn more about you.
Tyrosine Kinase Inhibitor
Erlotinib + Cabozantinib for Non-Small Cell Lung Cancer
Recruiting1 awardPhase 2
Peru, Illinois
This trial is testing the effectiveness of two drugs, either alone or in combination, as second or third line therapy for stage IV non-small cell lung cancer.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.